Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C, vaulted higher by as much as 21% after reporting positive data from an eight-week midstage study involving the combination of ACH-3102 and Gilead Sciences Sovaldi for genotype one patients.
So what: According to Achillion's early morning press release, the company's NS5A inhibitor, ACH-3102, when combined with Sovaldi over eight weeks, and without a ribavirin (which has been shown over the years to have its own unpleasant side effects), delivered a sustained virologic response in 100% of the 12 patients tested four weeks after treatment. Achillion plans on testing an additional 12 patients over a six-week, once-daily, treatment course of ACH-3102 and Sovaldi, and reporting its findings before year's end. Achillion also notes that ACH-3102 appeared safe and well-tolerated.
Now what: This is an important step for Achillion Pharmaceuticals because Gilead's Sovaldi is already on pharmacy shelves and racking up billions in sales, while AbbVie 's direct-acting antiviral combo is under review and on pace for a possible approval given its impressive clinical efficacy. Achillion needs to play catch-up as quickly as possible, and 100% SVR is certainly one way to open Wall Street and the medical community's eyes.
However, a few things to keep in context here. The studies conducted by Gilead and AbbVie that merited Sovaldi's approval and a new drug application from AbbVie were much larger than 12 patients. Obviously Achillion is going to need to run larger-scale phase three studies to demonstrate efficacy before the Food and Drug Administration would even consider an approval, but keep the size of this successful trial in mind as you wrap your hands around an appropriate valuation for Achillion.
Also, keep Achillion's development history in focus. It hasn't been able to move any compounds within its pipeline beyond phase two up until this point, so investors should be considering whether it has the funding and expertise to mount a successful large-scale phase three campaign and, assuming good results, the know-how to market an approved therapy.
Treating hepatitis C may represent a big opportunity for the biotech sector, but the potential growth behind this revolutionary technology may dwarf it!
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article Why Achillion Pharmaceuticals, Inc. Stock Soared originally appeared on Fool.com.
Sean Williamshas no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool owns shares of, and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.